We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ICRA

News List

Indian pharma industry estimated to grow nine to 11 per cent in 2021-22: ICRA ExpressPharma
January 06, 2022
The Indian pharma industry is estimated to grow at nine to 11 percent in 2021-22 and in the next few quarters, it will be driven by domestic and emerging markets, according to ratings agency ICRA.
Impact of COVID-19 2.0 on Indian pharma industry is minimal: ICRA expresspharma
July 05, 2021
In FY2022, ICRA sample set is estimated to witness Y-o-Y growth of 6-8 per cent in domestic market formulations, 5-7 per cent in US business and 8-10 per cent in European business.
PLI scheme to help India become Aatmanirbhar in APIs; boost investments in high-value generics: ICRA expresspharma
June 18, 2021
The production-linked incentive (PLI) schemes announced by the Government of India (GoI) for key raw materials such as bulk drugs and formulations, with a total incentive outlay of Rs. 210 billion will help the country become Aatmanirbhar.
Indian pharma industry continues to face headwinds; aggregate growth expected to come down to single expressbpd
March 08, 2017
ICRA expects growth trajectory for Indian pharmaceutical industry to moderate on back of slowing growth from the US, increased competition, and regulatory overhang along with base effect catching up.